Albireo Cash Flow from Operations

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

Albireo Pharma fundamentals help investors to digest information that contributes to Albireo Pharma's financial success or failures. It also enables traders to predict the movement of Albireo Stock. The fundamental analysis module provides a way to measure Albireo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Albireo Pharma stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

As of 22nd of March 2023, Net Cash Flow from Operations is likely to drop to about (99.4 M). In addition to that, Free Cash Flow is likely to drop to about (99.8 M).

Receivables Inventories

Albireo Cash Flow from Operations Analysis

Albireo Pharma's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

	2020	2021	2022	2023 (projected)
Revenues USD	8.31 M	40.58 M	46.67 M	50.35 M
Revenues	8.31 M	40.58 M	46.67 M	50.35 M

Revenues USD Revenues

Operating Cash Flow

EBITDA

Taxes

More About Cash Flow from Operations | All Equity Analysis

Current Albireo Pharma Cash Flow from Operations

(107.56 M)

Most of Albireo Pharma's fundamental indicators, such as Cash Flow from Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Albireo Cash Flow from Operations Driver Correlations

Understanding the fundamental principles of building solid financial models for Albireo Pharma is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Cash Flow from Operations. Since Albireo Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Albireo Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Albireo Pharma's interrelated accounts and indicators.

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Competition

Albireo Net Cash Flow from Operations

Net Cash Flow from Operations

(99.35 Million)

Albireo Pharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. Albireo Pharma reported last year Net Cash Flow from Operations of (96.8 Million)

In accordance with the recently published financial statements, Albireo Pharma has (107.56 Million) in Cash Flow from Operations. This is 120.4% lower than that of the Biotechnology sector and 272.03% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 111.07% higher than that of the company.

Albireo Cash Flow from Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Cash Flow from Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.

Albireo Pharma is currently under evaluation in cash flow from operations category among related companies.

Albireo Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.

	2018	2019	2020	2021	2022	2023 (projected)
Net Income Per Employee	(1.18 M)	(1.14 M)	(1.19 M)	(261.77 K)	(301.03 K)	(324.8 K)
Revenue Per Employee	326.67 K	175.2 K	92.06 K	312.15 K	358.97 K	360.48 K
Average Assets	199.19 M	172.87 M	240.71 M	266.95 M	307 M	331.23 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA	(41.21 M)	(57.29 M)	(96.08 M)	(19.82 M)	(17.84 M)	(19.25 M)
Earnings Before Interest Taxes and Depreciation Amortization USD	(41.21 M)	(57.29 M)	(96.08 M)	(19.82 M)	(17.84 M)	(19.25 M)
Earnings before Tax	(46.09 M)	(62.72 M)	(107.63 M)	(34.03 M)	(30.63 M)	(33.04 M)
Average Equity	142.23 M	105.98 M	148.89 M	154.69 M	177.89 M	191.93 M
Enterprise Value	120.02 M	179.83 M	446.4 M	196.32 M	225.76 M	188.69 M
Free Cash Flow	(26.85 M)	(53.46 M)	(101.11 M)	(108.02 M)	(97.22 M)	(99.78 M)
Invested Capital	(8.5 M)	(2.96 M)	1.41 M	1.34 M	1.54 M	1.66 M
Invested Capital Average	(5.73 M)	(3.27 M)	2.73 M	(872 K)	(784.8 K)	(846.76 K)
Market Capitalization	293.62 M	322.49 M	715.59 M	449 M	516.35 M	557.11 M
Tangible Asset Value	168.21 M	147.81 M	268.35 M	284.79 M	327.51 M	353.37 M
Working Capital	154.82 M	122.88 M	236.58 M	223.58 M	257.12 M	277.42 M

Albireo Fundamentals

	Return On Equity	(0.93) %
	Return On Asset	(0.25) %
	Profit Margin	(2.29) %
	Operating Margin	(2.15) %
	Current Valuation	259.98 M
	Shares Outstanding	20.74 M
	Shares Owned by Insiders	3.60 %
	Shares Owned by Institutions	96.40 %
	Number of Shares Shorted	553.91 K
	Price to Earning	(4.16) X
	Price to Book	4.30 X
	Price to Sales	7.35 X
	Revenue	40.58 M
	Gross Profit	39.22 M
	EBITDA	(19.82 M)
	Net Income	(34.03 M)
	Cash and Equivalents	180.97 M
	Cash per Share	9.23 X
	Total Debt	10 M
	Debt to Equity	0.18 %
	Current Ratio	4.49 X
	Book Value Per Share	4.84 X
	Cash Flow from Operations	(107.56 M)
	Short Ratio	0.86 X
	Earnings Per Share	(6.66) X
	Target Price	44.0
	Number of Employees	130
	Beta	1.04
	Market Capitalization	915.89 M
	Total Asset	302.05 M
	Retained Earnings	(171.75 M)
	Working Capital	26.76 M
	Current Asset	28.84 M
	Current Liabilities	2.07 M
	Z Score	54.6
	Net Asset	302.05 M

About Albireo Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

	Last Reported	Projected for 2023
Net Cash Flow from Operations	-96.8 M	-99.4 M
Free Cash Flow	-97.2 M	-99.8 M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-	0.87	ABIO	ARCA Biopharma	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.71	ACER	Acer Therapeutics	Financial Report 15th of May 2023	Pair Corr
-	0.59	AADI	Aadi Bioscience	Earnings Call This Week	Pair Corr
-	0.54	ACGN	Aceragen	Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Commodity Channel Index Use Commodity Channel Index to analyze current equity momentum
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Probability Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Equity Valuation Check real value of public entities based on technical and fundamental data

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

	Accounts Payable	Total Assets	Current Assets	Cash and Equivalents	Total Debt	Debt Current	Shareholders Equity	Total Liabilities	Current Liabilities	Tax Assets	Tax Liabilities
Accounts Payable		0.96	0.96	0.96	0.74	0.82	0.95	0.95	0.87	-0.28	-0.35
Total Assets	0.96		1.0	1.0	0.74	0.86	0.99	0.98	0.94	-0.32	-0.41
Current Assets	0.96	1.0		1.0	0.75	0.84	0.99	0.98	0.93	-0.3	-0.4
Cash and Equivalents	0.96	1.0	1.0		0.75	0.84	0.99	0.98	0.92	-0.3	-0.39
Total Debt	0.74	0.74	0.75	0.75		0.56	0.74	0.73	0.63	-0.22	-0.3
Debt Current	0.82	0.86	0.84	0.84	0.56		0.87	0.83	0.84	-0.44	-0.54
Shareholders Equity	0.95	0.99	0.99	0.99	0.74	0.87		0.96	0.9	-0.3	-0.39
Total Liabilities	0.95	0.98	0.98	0.98	0.73	0.83	0.96		0.96	-0.33	-0.43
Current Liabilities	0.87	0.94	0.93	0.92	0.63	0.84	0.9	0.96		-0.36	-0.47
Tax Assets	-0.28	-0.32	-0.3	-0.3	-0.22	-0.44	-0.3	-0.33	-0.36		0.98
Tax Liabilities	-0.35	-0.41	-0.4	-0.39	-0.3	-0.54	-0.39	-0.43	-0.47	0.98